Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.47 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.39 |
| ▸ | ITGAV | P06756 | 2/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.38 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL27747025 | 1.00 | CRBN (0.58) | CRBNLMNAEGLN1ALKBH5SUCNR1 | |
| Succinimide SCHEMBL29992516 | 0.93 | CRBN (0.50) | CRBNLMNAEGLN1ALKBH5SUCNR1 | |
| Succinic Acid SCHEMBL28918359 | 0.93 | CRBN (0.50) | CRBNLMNAEGLN1ALKBH5SUCNR1 | |
| Succinic Acid SCHEMBL27856042 | 0.93 | CRBN (0.50) | CRBNLMNAEGLN1ALKBH5SUCNR1 | |
| Adipic Acid SCHEMBL23851107 | 0.90 | LMNA (0.52) | CRBNLMNASLC22A6TSHRNFKB1 | |
| Succinic Acid SCHEMBL28684452 | 0.90 | CRBN (0.62) | CRBNLMNAEGLN1ALKBH5SUCNR1 | |
| Succinic Acid SCHEMBL28684449 | 0.90 | CRBN (0.62) | CRBNLMNAEGLN1ALKBH5SUCNR1 | |
| Adipic Acid SCHEMBL30526375 | 0.90 | LMNA (0.52) | CRBNLMNASLC22A6TSHRNFKB1 | |
| Glutarate SCHEMBL21542535 | 0.90 | CRBN (0.52) | CRBNLMNASLC22A6TSHRNFKB1 | |
| Glutarate SCHEMBL29990668 | 0.90 | CRBN (0.52) | CRBNLMNASLC22A6TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188142-A1 | POLYETHYLENE GLYCOL DERIVATIVE MODIFIED INTERLEUKIN-12, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | KANGLITAI BIOMEDICAL (QINGDAO) CO., LTD. (CN) | 2025-06-12 | — | — | US | claimed |
| CN-119258268-B | Hydrogel band-aid for bone repair and preparation method and application thereof | 山东大学 | 2025-05-30 | — | — | CN | claimed |
| CN-120053730-A | Tissue adhesive and preparation method and application thereof | 深圳聚环科技有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-119947711-A | Organogels for sustained drug delivery, methods of preparation and uses thereof | 视尔普斯眼科公司 | 2025-05-06 | — | — | CN | claimed |
| CN-116194091-B | Sustained release biodegradable lacrimal canaliculus insert comprising a hydrogel and a cyclosporin | 视尔普斯眼科公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119587742-A | Injectable dura mater sealant with adjustable mechanical properties, and preparation method and application thereof | 上海栎元医疗科技有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119499457-A | Coating composition for preventing medical instrument from crusting, and preparation method and application thereof | 中国科学院理化技术研究所 | 2025-02-25 | — | — | CN | claimed |
| CN-119424750-A | Medical dura mater (spinal) membrane repair hydrogel and kit | 天津市康尔医疗器械有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119278058-A | Single solution hydrogels with covalent bonds formed in situ, compositional designs, and medical procedures using the hydrogels | 普拉曼德有限责任公司 | 2025-01-07 | — | — | CN | claimed |
| CN-119258268-A | Hydrogel band-aid for bone repair and preparation method and application thereof | 山东大学 | 2025-01-07 | — | — | CN | claimed |
| CN-102309765-A | Long-acting anticoagulant polypeptide including immunoglobulin Fc segments as carriers and preparation method of same | BEIJING HANMEI PHARMACEUTICAL CO LTD | 2012-01-11 | — | — | CN | claimed |
| CN-102295704-A | Method for enhancing immunogenicity of micromolecular organic matter | — | 2011-12-28 | — | — | CN | claimed |
| CN-102234310-A | Polyethylene glycol modified protein separating and purifying method | Hangzhou jiuyuan gene engineering co ltd | 2011-11-09 | — | — | CN | claimed |
| CN-102028968-A | Surgical compositions | TYCO HEALTHCARE | 2011-04-27 | — | — | CN | claimed |
| CN-101352573-B | Recombinant human granulocyte colony stimulating factor lysine defect body modified by polyethyleneglycol | Hangzhou jiuyuan gene engineering co ltd | 2011-02-09 | — | — | CN | claimed |
| CN-101787117-A | Preparation method and application of polyethylene glycol-polysialic acid block copolymers | UNIV JIANGNAN | 2010-07-28 | — | — | CN | claimed |
| CN-101602801-A | The recombined human granular leukocyte colony stimulating factor mutant of modified by polyethyleneglycol | HANGZHOU JIUYUAN GENE ENGINEER (CN) | 2009-12-16 | — | — | CN | claimed |
| CN-101543630-A | Preparation and application of amphiphilic albumin derivative and pharmaceutical composition thereof | UNIV CHINA PHARMA | 2009-09-30 | — | — | CN | claimed |
| CN-101352573-A | Recombinant human granulocyte colony stimulating factor lysine defect body modified by polyethyleneglycol | HANGZHOU JIUYUAN GENE ENGINEER (CN) | 2009-01-28 | — | — | CN | claimed |
| CN-1500095-A | Polymer conjugates of neublastin and methods of using ssame | ¸ | 2004-05-26 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188142-A1 | POLYETHYLENE GLYCOL DERIVATIVE MODIFIED INTERLEUKIN-12, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CASP12, IL2, SUZ12 | CRBN 344/4885LMNA 2372/4885EGLN1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.